PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32751752-1 2020 We recently developed a blood-brain barrier (BBB)-penetrating enzyme transport vehicle (ETV) fused to the lysosomal enzyme iduronate 2-sulfatase (ETV:IDS) and demonstrated its ability to reduce glycosaminoglycan (GAG) accumulation in the brains of a mouse model of mucopolysaccharidosis (MPS) II. Glycosaminoglycans 194-211 iduronate 2-sulfatase Mus musculus 123-144 32631737-1 2020 Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disease (LSD) caused by a deficiency of the iduronate-2-sulfatase (IDS) that catabolizes glycosaminoglycans (GAGs). Glycosaminoglycans 151-169 iduronate 2-sulfatase Mus musculus 129-132 32751752-1 2020 We recently developed a blood-brain barrier (BBB)-penetrating enzyme transport vehicle (ETV) fused to the lysosomal enzyme iduronate 2-sulfatase (ETV:IDS) and demonstrated its ability to reduce glycosaminoglycan (GAG) accumulation in the brains of a mouse model of mucopolysaccharidosis (MPS) II. Glycosaminoglycans 213-216 iduronate 2-sulfatase Mus musculus 123-144 31193135-1 2019 Iduronate-2-sulfatase (IDS) is a lysosomal enzyme involved in the metabolism of the glycosaminoglycans heparan (HS) and dermatan (DS) sulfate. Glycosaminoglycans 84-102 iduronate 2-sulfatase Mus musculus 0-21 31193135-1 2019 Iduronate-2-sulfatase (IDS) is a lysosomal enzyme involved in the metabolism of the glycosaminoglycans heparan (HS) and dermatan (DS) sulfate. Glycosaminoglycans 84-102 iduronate 2-sulfatase Mus musculus 23-26 28478695-6 2017 Sustained IDS expression had a profound effect on normalization of GAG in all tested tissues and on prevention of hepatomegaly. Glycosaminoglycans 67-70 iduronate 2-sulfatase Mus musculus 10-13 29606503-2 2018 Since IDS catalyzes the degradation of glycosaminoglycans (GAGs), deficiency in this enzyme leads to accumulation of GAGs in most cells in all tissues and organs, resulting in severe somatic and neurological disorders. Glycosaminoglycans 39-57 iduronate 2-sulfatase Mus musculus 6-9 29978271-1 2018 Mucopolysaccharidosis II (MPS II) is caused by a deficiency of iduronate-2-sulfatase that results in accumulation of glycosaminoglycans (GAG), including heparan sulfate (HS), which is considered to contribute to neuropathology. Glycosaminoglycans 117-135 iduronate 2-sulfatase Mus musculus 63-84 29978271-1 2018 Mucopolysaccharidosis II (MPS II) is caused by a deficiency of iduronate-2-sulfatase that results in accumulation of glycosaminoglycans (GAG), including heparan sulfate (HS), which is considered to contribute to neuropathology. Glycosaminoglycans 137-140 iduronate 2-sulfatase Mus musculus 63-84 30064964-1 2018 Mucopolysaccharidosis type II (MPS II or Hunter syndrome) is a lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase (IDS), an enzyme that catabolizes glycosaminoglycans (GAGs) including heparan sulfate (HS) and dermatan sulfate (DS). Glycosaminoglycans 172-190 iduronate 2-sulfatase Mus musculus 139-142 25761450-1 2015 Mucopolysaccharidosis type II (MPS II) is a neuropathic lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase (IDS), which leads to the accumulation of glycosaminoglycans (GAGs). Glycosaminoglycans 173-191 iduronate 2-sulfatase Mus musculus 132-135 27699273-1 2016 Mucopolysaccharidosis type II (MPSII) is an X-linked lysosomal storage disease characterized by severe neurologic and somatic disease caused by deficiency of iduronate-2-sulfatase (IDS), an enzyme that catabolizes the glycosaminoglycans heparan and dermatan sulphate. Glycosaminoglycans 218-236 iduronate 2-sulfatase Mus musculus 158-179 27699273-1 2016 Mucopolysaccharidosis type II (MPSII) is an X-linked lysosomal storage disease characterized by severe neurologic and somatic disease caused by deficiency of iduronate-2-sulfatase (IDS), an enzyme that catabolizes the glycosaminoglycans heparan and dermatan sulphate. Glycosaminoglycans 218-236 iduronate 2-sulfatase Mus musculus 181-184 23529876-1 2013 Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome (OMIM 309900), is a rare, X-linked lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase (IDS; EC 3.1.6.13), which is involved in the lysosomal degradation of glycosaminoglycans (GAG). Glycosaminoglycans 250-268 iduronate 2-sulfatase Mus musculus 158-179 23529876-4 2013 The results showed that the group treated with 12 microg/day doses of rh-IDS demonstrated decreased GAG concentrations compared to the untreated KO mice group (P = 0.003). Glycosaminoglycans 100-103 iduronate 2-sulfatase Mus musculus 73-76 22704483-1 2012 Mucopolysaccharidosis type II (MPS II), or Hunter syndrome, is a lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase (IDS) and is characterized by the accumulation of glycosaminoglycans (GAGs). Glycosaminoglycans 190-208 iduronate 2-sulfatase Mus musculus 141-144 22279584-8 2012 Lumbar administration of recombinant I2S to enzyme deficient animals reduced the storage of glycosaminoglycans in both superficial and deep brain tissues, with concurrent morphological improvements. Glycosaminoglycans 92-110 iduronate 2-sulfatase Mus musculus 37-40 21319344-10 2011 A higher dose of IdS infusion in MPS II mice led to disappearance of lysosomal GAG and restoration of glycogen to the cytoplasm of hepatocytes. Glycosaminoglycans 79-82 iduronate 2-sulfatase Mus musculus 17-20 17459751-1 2007 Mucopolysaccharidosis II (MPS II; Hunter syndrome) is an X-linked metabolic disorder caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (I2S), which catalyzes the catabolism of glycosaminoglycans (GAG) by cleaving the O-linked sulfate from dermatan sulfate and heparan sulfate. Glycosaminoglycans 195-213 iduronate 2-sulfatase Mus musculus 132-153 17459751-1 2007 Mucopolysaccharidosis II (MPS II; Hunter syndrome) is an X-linked metabolic disorder caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (I2S), which catalyzes the catabolism of glycosaminoglycans (GAG) by cleaving the O-linked sulfate from dermatan sulfate and heparan sulfate. Glycosaminoglycans 195-213 iduronate 2-sulfatase Mus musculus 155-158 17459751-1 2007 Mucopolysaccharidosis II (MPS II; Hunter syndrome) is an X-linked metabolic disorder caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (I2S), which catalyzes the catabolism of glycosaminoglycans (GAG) by cleaving the O-linked sulfate from dermatan sulfate and heparan sulfate. Glycosaminoglycans 215-218 iduronate 2-sulfatase Mus musculus 132-153 17459751-1 2007 Mucopolysaccharidosis II (MPS II; Hunter syndrome) is an X-linked metabolic disorder caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (I2S), which catalyzes the catabolism of glycosaminoglycans (GAG) by cleaving the O-linked sulfate from dermatan sulfate and heparan sulfate. Glycosaminoglycans 215-218 iduronate 2-sulfatase Mus musculus 155-158 15966019-1 2005 BACKGROUND: Hunter syndrome, mucopolysaccharidosis type II (MPS II), is a X-linked inherited disorder caused by the deficiency of the enzyme iduronate-2-sulfatase (IDS), involved in the lysosomal catabolism of the glycosaminoglycans (GAG) dermatan and heparan sulfate. Glycosaminoglycans 214-232 iduronate 2-sulfatase Mus musculus 141-162 15966019-1 2005 BACKGROUND: Hunter syndrome, mucopolysaccharidosis type II (MPS II), is a X-linked inherited disorder caused by the deficiency of the enzyme iduronate-2-sulfatase (IDS), involved in the lysosomal catabolism of the glycosaminoglycans (GAG) dermatan and heparan sulfate. Glycosaminoglycans 214-232 iduronate 2-sulfatase Mus musculus 164-167 15966019-1 2005 BACKGROUND: Hunter syndrome, mucopolysaccharidosis type II (MPS II), is a X-linked inherited disorder caused by the deficiency of the enzyme iduronate-2-sulfatase (IDS), involved in the lysosomal catabolism of the glycosaminoglycans (GAG) dermatan and heparan sulfate. Glycosaminoglycans 234-237 iduronate 2-sulfatase Mus musculus 141-162 15966019-1 2005 BACKGROUND: Hunter syndrome, mucopolysaccharidosis type II (MPS II), is a X-linked inherited disorder caused by the deficiency of the enzyme iduronate-2-sulfatase (IDS), involved in the lysosomal catabolism of the glycosaminoglycans (GAG) dermatan and heparan sulfate. Glycosaminoglycans 234-237 iduronate 2-sulfatase Mus musculus 164-167 8325651-1 1993 Iduronate sulfatase (IDS; EC 3.1.6.13) is a lysosomal enzyme that acts on sulfate groups on C-2 positions of iduronic acid residues of the mucopolysaccharides dermatan and heparan sulfate. Glycosaminoglycans 139-158 iduronate 2-sulfatase Mus musculus 0-19 34622797-1 2021 Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder caused by deficiency of the iduronate-2-sulfatase (IDS) enzyme, resulting in cellular accumulation of glycosaminoglycans (GAGs) throughout the body. Glycosaminoglycans 173-191 iduronate 2-sulfatase Mus musculus 99-120 34622797-1 2021 Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder caused by deficiency of the iduronate-2-sulfatase (IDS) enzyme, resulting in cellular accumulation of glycosaminoglycans (GAGs) throughout the body. Glycosaminoglycans 173-191 iduronate 2-sulfatase Mus musculus 122-125 35284671-1 2022 Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a rare X-linked recessive disease caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS), which activates intracellular accumulation of nonmetabolized glycosaminoglycans such as heparan sulfate and dermatan sulfate. Glycosaminoglycans 245-263 iduronate 2-sulfatase Mus musculus 178-181 35284671-1 2022 Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a rare X-linked recessive disease caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS), which activates intracellular accumulation of nonmetabolized glycosaminoglycans such as heparan sulfate and dermatan sulfate. Glycosaminoglycans 245-263 iduronate 2-sulfatase Mus musculus 155-176